Printed From BioPortfolio.com
Keytruda falls hard at gastric cancer hurdle
05:19 EST 18 Dec 2017 | Pharmafile
There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits of the therapies are beginning to be found with a series of surprise failures across a number of indications.
The first major one was Opdivo’s failure as first-line treatment in lung cancer, after this ice-breaker, of sorts, there have been a number of subsequent failures that have called into question how far the treatments can be pushed.
Original Article: Keytruda falls hard at gastric cancer hurdle
